Age-related decline in muscle mass and strength, termed sarcopenia, is a primary contributor to mobility problems, frailty, and institutionalization among older adults. Nearly half of all U.S. elders have low muscle mass or strength and the associated direct healthcare costs are estimated to exceed $18 billion per year. These numbers will only increase as the population of older adults continues to expand and live longer. Yet despite the major public health impact of sarcopenia there is no accepted clinical definition and no effective therapies that can be used to prevent or reverse sarcopenia.
Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated With Low Muscle Mass in Older Adults: The FNIH Sarcopenia Project
The Foundation for the National Institutes of Health (FNIH) Research Award
The goal of this project is to analyze existing data sets to support the development of guidelines for the diagnosis of sarcopenia, muscle weakness, and indicators of treatment benefit.
Association of Protein Intake with Lean Mass and Muscle Strength in the Framingham Offspring Study
Unrestricted grant funding from the General Mills Bell Institute of Health and Nutrition
The goal of this proposal is to examine the cross-sectional and longitudinal association of measures of protein intake (total, animal and plant protein) with muscle strength and to determine whether lean mass represents an important part of the potential biologic pathway involving protein and muscle strength in the Framingham Offspring Study.
Protein Food Clusters and Measures of Bone Mineral Density and Muscle Strength
Harvard Translational Research in Aging training Program, NIA T-32 grant
The goal of this study is to investigate the relation of protein food groups (as defined by cluster analysis) with bone mineral density and muscle strength using the data from the Framingham Osteoporosis Study.